Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-24T17:08:58.307Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of atypical antipsychotics in the treatment of catatonia

Published online by Cambridge University Press:  16 April 2020

Filip Van Den Eede ,
Jan Van Hecke ,
Arjen Van Dalfsen ,
Bart Van den Bossche ,
Paul Cosyns  and
Bernard G.C. Sabbe
Filip Van Den Eede*
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, CAPRI, University of Antwerp (UA), Campus Drie Eiken/Building T, Universiteitsplein 1, 2610Antwerp, Belgium University Hospital Antwerp, UZA, Edegem, Belgium
Jan Van Hecke
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, CAPRI, University of Antwerp (UA), Campus Drie Eiken/Building T, Universiteitsplein 1, 2610Antwerp, Belgium Campus Stuivenberg, ACZA, Antwerp, Belgium
Arjen Van Dalfsen
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, CAPRI, University of Antwerp (UA), Campus Drie Eiken/Building T, Universiteitsplein 1, 2610Antwerp, Belgium Mental Health Care WNB, Bergen op Zoom, The Netherlands
Bart Van den Bossche
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, CAPRI, University of Antwerp (UA), Campus Drie Eiken/Building T, Universiteitsplein 1, 2610Antwerp, Belgium University Hospital Antwerp, UZA, Edegem, Belgium
Paul Cosyns
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, CAPRI, University of Antwerp (UA), Campus Drie Eiken/Building T, Universiteitsplein 1, 2610Antwerp, Belgium University Hospital Antwerp, UZA, Edegem, Belgium
Bernard G.C. Sabbe
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, CAPRI, University of Antwerp (UA), Campus Drie Eiken/Building T, Universiteitsplein 1, 2610Antwerp, Belgium Psychiatric Hospital St.-Norbertushuis, Duffel, Belgium
*
*Corresponding author. Tel.: +32 3 820 2328. E-mail address: [email protected] (F. Van Den Eede).
Get access

Abstract

Purpose

Evidence indicates that classical antipsychotics may aggravate non-malignant and malignant catatonia (MC). Atypical antipsychotics are less likely to cause movement disorders than classical antipsychotics and they are being frequently prescribed in disorders that can be associated with catatonia. Therefore, the important question that arises is whether atypical antipsychotics have a role to play in the treatment of catatonia.

Materials and methods

A Medline search was performed to locate papers on the use of atypical antipsychotics in catatonia published between 1970 and 31st December 2004.

Results

The literature on the use of atypical antipsychotics in catatonia consists of case reports and retrospective studies. In most cases of non-MC a reduction of the catatonic symptoms is reported upon treatment with atypical antipsychotics. Cases of MC relate mainly to the neuroleptic malignant syndrome (NMS), which is considered as an iatrogenic stuporous variant of MC caused by antipsychotics.

Conclusion

There are indications that atypical antipsychotics may be useful in non-MC. As a consequence, one should not only focus on the possible extrapyramidal and autonomic side effects of these drugs, but also on the possible beneficial effects on certain brain functions and on the catatonic symptomatology. However, randomized controlled trials are needed to evaluate the effect of these drugs, and caution is advisable, since cases of NMS have been linked to treatment with atypical antipsychotics. There is no evidence to prescribe atypical antipsychotics in MC.

Keywords

CatatoniaLethal catatoniaMalignant catatoniaNeuroleptic malignant syndromeAtypical antipsychotics
Type
Review
Information
European Psychiatry , Volume 20 , Issue 5-6 , August 2005 , pp. 422 - 429
Copyright
Copyright ©Elsevier SAS 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Abbreviations: ECT, electroconvulsive therapy; MC, malignant catatonia; NMS, neuroleptic malignant syndrome; non-MC, non-malignant catatonia.

References

Albucher, R.C., DeQuardo, J., Tandon, R.Treatment of catatonia with an anticholinergic agent. Biol. Psychiatry 1991; 29: 508–517CrossRefGoogle ScholarPubMed
American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4th ed Washington, DCAPA 1994Google Scholar
Ananth, J., Burgoyne, K.S., Gadasalli, R., Aquino, S.How do the atypical antipsychotics work? J. Psychiatry Neurosci. 2001; 26: 385–394Google ScholarPubMed
Ananth, J., Parameswaran, S., Gunatilake, S., Burgoyne, K., Sidhom, T.Neuroleptic malignant syndrome and atypical antipsychotic drugs. J. Clin. Psychiatry 2004; 65: 464–470CrossRefGoogle ScholarPubMed
Arnt, J., Skarsfeldt, T.Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63–101CrossRefGoogle Scholar
Bahro, M., Kämpf, C., Strnad, J.Catatonia under medication with risperidone in a 61-year-old patient. Acta Psychiatr. Scand. 1999; 99: 223–226CrossRefGoogle Scholar
Blummer, D.Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings. Compr. Psychiatry 1997; 38: 193–201CrossRefGoogle Scholar
Braunig, P., Kruger, S., Shugar, G., Hoffler, J., Borner, I.The catatonia rating scale I—development, reliability, and use. Compr. Psychiatry 2000; 2: 147–158CrossRefGoogle Scholar
Bush, G., Fink, M., Petrides, G., Dowling, F., Francis, A.Catatonia. I. Rating scale and standardized examination. Acta Psychiatr. Scand. 1996; 93: 129–136CrossRefGoogle ScholarPubMed
Bush, G., Fink, M., Petrides, G., Dowling, F., Francis, A.Catatonia II. Treatment with orazepam and electroconvulsive therapy. Acta Psychiatr. Scand. 1996; 93: 137–143CrossRefGoogle Scholar
Carroll, B.T., Lee, J.W.Catatonia is a risk factor for neuroleptic malignant syndrome. J. Clin. Psychiatry 2004; 65: 1722–1723CrossRefGoogle ScholarPubMed
Carroll, B.T., Taylor, R.E.The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J. Clin. Psychopharmacol. 1997; 17: 235–236CrossRefGoogle ScholarPubMed
Cassidy, E.M., O’Brien, M., Osman, M.F., Finucane, J., O’Keane, V.Lethal catatonia responding to high-dose olanzapine therapy. J. Clin. Psychopharmacol. 2001; 15: 302–304CrossRefGoogle ScholarPubMed
Castillo, E., Rubin, R.T., Holsboer-Trachsler, E.Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am. J. Psychiatry 1989; 146: 324–328Google ScholarPubMed
Caroff, S.N., Mann, S.C., Campbell, E.C., Sullivan, K.A.Movement disorders associated with atypical antipsychotic drugs. J. Clin. Psychiatry 2002; 63: 12–19Google ScholarPubMed
Cook, E.H., Olson, K., Pliskin, N.Response of organic catatonia to risperidone. Arch. Gen. Psychiatry 1996; 53: 82–83CrossRefGoogle Scholar
Filice, G.A., McDougall, B.C., Ercan Fang, N., Billington, C.J.Neuroleptic malignant syndrome associated with olanzapine. Ann. Pharmacother. 1998; 32: 1158–1159CrossRefGoogle ScholarPubMed
Fink, M.Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry 1996; 39: 1–4CrossRefGoogle ScholarPubMed
Fink, M.Catatonia: syndrome or schizophrenia subtype? Recognition and treatment. J. Neural Transm. 2001; 108: 637–644CrossRefGoogle ScholarPubMed
Fink, M., Taylor, M.A.Catatonia. A clinicians guide to diagnosis and treatment. 1st ed CambridgeCambridge University Press 2003CrossRefGoogle Scholar
Fleischhacker, W.W., Unterweger, B., Kane, J.M., Hinterhuber, H.The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr. Scand. 1990; 81: 3–5CrossRefGoogle ScholarPubMed
Fricchione, G.L.Neuroleptic catatonia and its relationship to psychogenic catatonia. Biol. Psychiatry 1985; 20: 304–313CrossRefGoogle ScholarPubMed
Gurrera, R.J.Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am. J. Psychiatry 1999; 156: 169–180Google ScholarPubMed
Hasan, S., Buckley, P.Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am. J. Psychiatry 1998; 155: 1113–1116CrossRefGoogle ScholarPubMed
Hawkins, J.M., Archer, K.J., Strakowski, S.M., Keck, P.E.Somatic treatment of catatonia. Int. J. Psychiatry Med. 1995; 25: 345–369CrossRefGoogle ScholarPubMed
Hesslinger, B., Walden, J., Normann, C.Acute and long-term treatment of catatonia with risperidone. Pharmacopsychiatry 2001; 34: 25–26CrossRefGoogle ScholarPubMed
Kahlbaum, L.Die Katatonie oder das Spannungsirresein, Eine klinische Form psychischer Krankheit 2000 Nijmegen: Arts & Boeve (1874)Google Scholar
Kapur, S., Seeman, P.Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry 2001; 158: 360–369CrossRefGoogle ScholarPubMed
Kewalsing, J.S., Ramaekers, G.M.G.I., Van Harten, P.N.Neuroleptic malignant syndrome and quetiapine. Am. J. Psychiatry 2002; 159: 149–150Google Scholar
Koch, M., Chandragiri, S., Rizvi, S., Petrides, G., Francis, A.Catatonic signs in neuroleptic malignant syndrome. Compr. Psychiatry 2000; 41: 73–75CrossRefGoogle ScholarPubMed
Kohen, D., Bristow, M.F.Atypical antipsychotics and neuroleptic malignant syndrome. Br. J. Psychiatry 1999; 175: 392–393CrossRefGoogle ScholarPubMed
Kopala, L.C., Caudle, C.Acute and longer-term effects of risperidone in a case of first-episode catatonic schizofrenia. J. Psychopharmacol. 1998; 12: 314–317CrossRefGoogle Scholar
Krüger, S., Cooke, R.G., Spegg, C.C., Bräunig, P.Relevance of the catatonic syndrome to the mixed manic episode. J. Affect. Disord. 2003; 74: 279–285CrossRefGoogle ScholarPubMed
Lauterbach, E.C.Catatonia-like events after valproic acid with risperidone and sertraline. Neuropsychiatry Neuropsychol. Behav. Neurol. 1998; 11: 157–163Google ScholarPubMed
Lee, J.W.Y., Robertson, S.Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report. Ann. Clin. Psychiatr. 1997; 9: 165–169CrossRefGoogle ScholarPubMed
Leucht, S., Pitschel-Walz, G., Engel, R.R., Kissling, W.Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 2002; 159: 180–190CrossRefGoogle ScholarPubMed
Levenson, J.L.Neuroleptic malignant syndrome. Am. J. Psychiatry 1985; 142: 1137–1145Google ScholarPubMed
Llorca, P.M., Penault, F., Lançon, C., Dufumier, E., Vaiva, G.Notion de psychose d’hypersensibilité. Cas particulier de la clozapine. Encephale 1999; XXV: 638–644Google Scholar
Lopez-Canino, A., Francis, A.Drug-induced catatonia. Caraoff, S.N., Mann, S.C., Francis, A., Fricchione, G.L.Catatonia: from psychopathology to neurobiology ArlingtonAmerican Psychiatric Publishing 2004 129–139Google Scholar
Mann, S.C., Caroff, S.N., Bleier, H.R., Welz, W.K.R., Kling, M.A., Hayashida, M.Lethal catatonia. Am. J. Psychiatry 1986; 143: 1374–1381Google ScholarPubMed
Mann, S.C., Auriacombe, M., Macfadden, W., Caroff, S.N., Campbell, E.C., Tignol, J.La catatonie léthale: aspects cliniques et conduite thérapeutique. Une revue de la littérature. Encephale 2001; XXVII: 213–216Google Scholar
Martényi, F., Metcalfe, S., Schausberger, B., Dossenbach, M.R.K.An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. J. Clin. Psychiatry 2001; 62: 25–27Google ScholarPubMed
Meltzer, H.Multiple neurotransmitters involved in antipsychotic drug action. Kapur, S., Lecrubier, Y.Dopamine in the pathophysiology and treatment of schizophrenia LondonMartin Dunitz 2003 177–205CrossRefGoogle Scholar
Naber, D., Holzbach, R., Perro, C., Hippius, H.Clinical management of clozapine patients in relation to efficacy and side-effects. Br. J. Psychiatry 1992; 160: 54–59CrossRefGoogle Scholar
Northoff, G.Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J. Neural Transm. 2002; 109: 1453–1467CrossRefGoogle ScholarPubMed
Northoff, G., Koch, A., Wenke, J., Eckert, J., Boker, H., Pflug, B., Bogerts, B.Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms. Mov. Disord. 1999; 14: 404–4163.0.CO;2-5>CrossRefGoogle ScholarPubMed
Northoff, G., Kotter, R., Baumgart, F., Danos, P., Boeker, H., Kaulisch, T., et al.Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation. Schizophr. Bull. 2004; 30: 405–427CrossRefGoogle ScholarPubMed
Northoff, G., Steinke, R., Czcervenka, C., Krause, R., Ulrich, S., Danos, P., et al.Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J. Neurol. Neurosurg. Psychiatry 1999; 67: 445–450CrossRefGoogle ScholarPubMed
Philbrick, K.L., Rummans, T.A.Malignant catatonia. J. Neuropsychiatry Clin. Neurosci. 1994; 6: 1–13Google ScholarPubMed
Pommepuy, N., Januel, D.La catatonie: résurgence d'un concept. Une revue de la littérature internationale. Encephale 2002; XXVII: 481–492Google Scholar
Rommel, O., Tegenthoff, M., Widdig, W., Bräunig, P., Malin, J.P.Organic catatonia following frontal lobe injury: response to clozapine. J. Neuropsychiatr. 1998; 10: 237–238CrossRefGoogle ScholarPubMed
Rosebush, P.I., Mazurek, M.F.Catatonia: re-awakening to a forgotten disorder. Mov. Disord. 1999; 14: 395–3973.0.CO;2-L>CrossRefGoogle ScholarPubMed
Rosebush, P.I., Hildebrand, A.M., Furlong, B.G., Mazurek, M.F.Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J. Clin. Psychiatry 1990; 51: 357–362Google Scholar
Rosebush, P.I., Stewart, T., Mazurek, M.F.The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J.Psychiatry 1991; 159: 709–712CrossRefGoogle ScholarPubMed
Singerman, B., Raheja, R.Malignant catatonia—a continuing reality. Ann. Clin. Psychiatry 1994; 6: 259–266CrossRefGoogle Scholar
Taylor, M.A., Fink, M.Catatonia in psychiatric classification: a home of is own. Am. J. Psychiatry 2003; 160: 1233–1241CrossRefGoogle ScholarPubMed
Ungvari, G.S., Caroll, B.T.Foundations for the classification of catatonias. Mov. Disord 2000; 15: 180–1813.0.CO;2-K>CrossRefGoogle ScholarPubMed
Ungvari, G.S., Chiu, H.F.K., Chow, L.Y., Lau, B.T.S., Tang, W.K.Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology 142 1999 393–398 (Berl.)CrossRefGoogle Scholar
Ungvari, G.S., Leung, C.M., Wong, M.K., Lau, J.Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr. Scand. 1994; 89: 285–288CrossRefGoogle ScholarPubMed
Valevski, A., Loebl, T., Keren, T., Bodinger, L., Weizman, A.Response of catatonia to risperidone: two case reports. Clin. Neuropharmacol. 2001; 24: 228–231CrossRefGoogle ScholarPubMed
Van Den Eede, F., Sabbe, B.Catatonia in psychiatric classification. Am. J. Psychiatry 2004; 161: 2327–2328CrossRefGoogle ScholarPubMed
Van der Heijden, F.M.M.A., Tuinier, S., Pepplinkhuizen, L., Verhoeven, W.M.A.Catatonia: the rise and fall of an intriguing psychopathological dimension. Acta Neuropsychiatr. 2002; 14: 111–116CrossRefGoogle ScholarPubMed
White, D.A.C., Robins, A.H.Catatonia: harbinger of the neuroleptic malignant syndrome. Br. J. Psychiatry 1991; 158: 419–421CrossRefGoogle ScholarPubMed
Woodburne, O., Nunez, L., Nunez, C.Y.Use of ziprasidone to treat bipolar-associated catatonia. Bipolar Disord. 2004; 6: 166–167Google Scholar
Yeh, A.W., Lee, J.W., Cheng, T.C., Wen, J.K., Chen, W.H.Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report. Clin. Neuropharmacol. 2004; 27: 216–218CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.